cancernetwork - Robuta Search

https://www.cancernetwork.com/authors/christian-j-nelson-phd Christian J. Nelson, PhD | Authors | CancerNetwork christian j nelson phd authors https://www.cancernetwork.com/view/background-18f-fluciclovine-and-68ga-psma-11-imaging-in-prostate-cancer Background: 18F-Fluciclovine and 68Ga-PSMA-11 Imaging in Prostate Cancer | CancerNetwork May 17, 2026 - Drs Steven Finkelstein and Louis J. Mazzarelli comment on limitations associated with conventional imaging modalities in prostate cancer and highlight the... https://www.cancernetwork.com/authors/matthew-biagioli-md Matthew Biagioli, MD | Authors | CancerNetwork matthew md authors cancernetwork https://www.cancernetwork.com/view/daily-chg-bathing-initiatives-reduced-clabsi Daily CHG Bathing Initiatives Reduced CLABSI | CancerNetwork May 15, 2026 - Detailed education and other initiatives related to CHG cloth use boosted bathing compliance rates by 95% in 14 months, and decreased CLABSI by 8%. daily chg bathing initiatives reduced https://www.cancernetwork.com/view/identifying-uses-for-immunotherapy-across-sarcoma-populations-and-subtypes Identifying Uses for Immunotherapy Across Sarcoma Populations and Subtypes | CancerNetwork May 10, 2026 - Microsatellite instability-high status may make patients suitable candidates to receive agents like pembrolizumab, according to Steven Bialick, DO. uses for identifying immunotherapy across sarcoma https://www.cancernetwork.com/view/seribantumab-fails-improve-pfs-ovarian-cancer-some-patients-may-benefit Seribantumab Fails to Improve PFS in Ovarian Cancer; Some Patients May Benefit | CancerNetwork May 19, 2026 - Adding seribantumab to paclitaxel failed to improved progression-free survival in unselected patients with platinum-resistant or -refractory ovarian cancer.... https://www.cancernetwork.com/view/treatment-considerations-for-transplant-ineligible-multiple-myeloma Treatment Considerations for Transplant-Ineligible Multiple Myeloma | CancerNetwork May 10, 2026 - Radowan A. Elnair, MD, and Sarah A. Holstein, MD, PhD, review literature regarding progress in the management of the transplant-ineligible multiple myeloma in... multiple myeloma treatment considerations transplant ineligible https://www.cancernetwork.com/view/treating-troops-model-battling-health-care-disparities Treating the Troops: A Model for Battling Health-Care Disparities | CancerNetwork May 21, 2026 - There are many characteristics that set the military apart from the general population. But there was one particularly appealing characteristic: It is an... health care disparities treating troops model https://www.cancernetwork.com/view/payers-may-ignore-aspects-care-most-important-patients Payers May Ignore Aspects of Care Most Important to Patients | CancerNetwork May 14, 2026 - CHICAGO-As the health care system in this country shifts from fee for service to managed care, private and public payers are being forced to make decisions... most important payers may ignore aspects https://www.cancernetwork.com/view/oral-vinorelbine-promising-advanced-breast-cancer-patients Oral Vinorelbine Is Promising in Advanced Breast Cancer Patients | CancerNetwork May 15, 2026 - BOULOGNE, France-An oral formulation of vinorelbine (Navelbine) demonstrated encouraging antitumor activity and proved to be well tolerated in a phase I study... advanced breast cancer oral promising patients cancernetwork https://www.cancernetwork.com/view/early-impressions-high-intensity-focused-ultrasound-prostate-cancer Early Impressions of High-Intensity Focused Ultrasound for Prostate Cancer | CancerNetwork May 16, 2026 - The use of high-intensity focused ultrasound (HIFU) as a method for ablation of a localized tumor growth is not new. Several attempts have been made to apply... high intensity focused ultrasound prostate cancer early impressions https://www.cancernetwork.com/view/more-updates-ash-2010 More Updates from ASH 2010 | CancerNetwork more updates ash cancernetwork https://www.cancernetwork.com/view/durvalumab-combo-shows-consistent-outcomes-in-advanced-pleural-mesothelioma Durvalumab Combo Shows Consistent Outcomes in Advanced Pleural Mesothelioma | CancerNetwork May 19, 2026 - Slow accrual led to the early stopping of the phase 3 DREAM3R trial assessing durvalumab/chemotherapy in advanced pleural mesothelioma. pleural mesothelioma combo shows consistent outcomes https://www.cancernetwork.com/view/genetic-tests-further-complicate-ovarian-cancer-controversies Genetic Tests Further Complicate Ovarian Cancer Controversies | CancerNetwork May 15, 2026 - Oncologists still have no screening test that reliably can detect ovarian cancer in its early stages, and recent genetic advances, while shedding new light on... genetic tests ovarian cancer complicate controversies cancernetwork https://www.cancernetwork.com/view/ash-2010-intro ash 2010 intro | CancerNetwork May 20, 2026 - Dear Colleague: In recent years, experts in the field of hematologic malignancies have seen a panoply of drugs gain a place in our treatment armamentarium.... ash intro cancernetwork https://www.cancernetwork.com/view/envafolimab-produces-ongoing-responses-tolerability-in-sarcoma-subtypes Envafolimab Produces Ongoing Responses, Tolerability in Sarcoma Subtypes | CancerNetwork May 10, 2026 - The agent continues to produce ongoing responses in a cohort of patients with undifferentiated pleomorphic sarcoma or myxofibrosarcoma in the phase 2 ENVASARC... sarcoma subtypes produces ongoing responses cancernetwork https://www.cancernetwork.com/view/swedish-study-supports-mammography-screening-women-age-40-49 Swedish Study Supports Mammography Screening for Women Age 40 to 49 | CancerNetwork May 19, 2026 - Areview of major clinical trials strongly supports the value of mammography screening for women in their 40s. The review showed a 24% decrease in deaths from... for women https://www.cancernetwork.com/authors/jennifer-kelly-shepphird-phd Jennifer Kelly Shepphird, PhD | Authors | CancerNetwork jennifer kelly phd authors cancernetwork https://www.cancernetwork.com/view/high-risk-women-less-likely-perform-bse-regularly High-Risk Women Less Likely to Perform BSE Regularly | CancerNetwork May 19, 2026 - PALM SPRINGS, Calif--Women often develop idiosyncratic ideas about their risk for breast cancer, Mary Jane Massie, MD, said at the Academy of Psychosomatic... high risk less likely women perform bse https://www.cancernetwork.com/view/european-commission-oks-epcoritamab-for-r-r-diffuse-large-b-cell-lymphoma European Commission OKs Epcoritamab for R/R Diffuse Large B-Cell Lymphoma | CancerNetwork May 21, 2026 - The conditional marketing approval of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma is based on data from the phase 1/2 EPCORE NHL-1 study. european commission https://www.cancernetwork.com/view/fda-approves-gleevec-use-inoperable-or-metastatic-gists FDA Approves Gleevec for Use in Inoperable or Metastatic GISTs | CancerNetwork May 10, 2026 - ROCKVILLE, Maryland-The Food and Drug Administration (FDA) has approved the use of Gleevec (imatinib mesylate, Novartis) for the treatment of c-kit-positive... fda approves use https://www.cancernetwork.com/authors/andrew-m-evens-do-ms Andrew M. Evens, DO, MBA, MSc | Authors | CancerNetwork andrew m evens mba msc authors https://www.cancernetwork.com/contact-us Contact Us | CancerNetwork Contact Us | CancerNetwork us cancernetwork https://www.cancernetwork.com/authors/steven-e-benner-md Steven E. Benner, MD | Authors | CancerNetwork steven benner md authors cancernetwork https://www.cancernetwork.com/clinical/leukemia?page=11 Leukemia | Clinical | Page 11 | CancerNetwork leukemia clinical cancernetwork https://www.cancernetwork.com/clinical/radiation-oncology Radiation Oncology | Clinical | CancerNetwork radiation oncology clinical cancernetwork https://www.cancernetwork.com/view/risk-stratification-and-shared-decision-making-in-early-relapse-multiple-myeloma Risk Stratification and Shared Decision-Making in Early Relapse Multiple Myeloma | CancerNetwork shared decision making risk stratification https://www.cancernetwork.com/authors/carlos-h-barrios Carlos H Barrios | Authors | CancerNetwork carlos h barrios cancernetwork https://www.cancernetwork.com/view/imatinib-provides-lasting-treatment-patients-advanced-gists Imatinib Provides Lasting Treatment for Patients With Advanced GISTs | CancerNetwork May 19, 2026 - Imatinib mesylate (Gleevec) has a lasting effect on advanced gastrointestinal stromal tumors (GISTs), while greatly reducing treatment for imatinib provides lasting patients https://www.cancernetwork.com/view/bills-would-require-private-insurers-pay-cancer-screening Bills Would Require Private Insurers to Pay for Cancer Screening | CancerNetwork May 14, 2026 - Members of Congress are trying to assure coverage of cancer screening tests under private insurance plans that Congress equired Medicare to cover as part of... to pay cancer screening bills would require https://www.cancernetwork.com/around-the-practice/advances-in-the-field-of-myelofibrosis Advances in the Field of Myelofibrosis | Around the Practice | CancerNetwork in the field advances myelofibrosis around practice https://www.cancernetwork.com/view/age-patients-thin-melanomas-consideration-slnb-recommendations Age of Patients With Thin Melanomas a Consideration in SLNB Recommendations | CancerNetwork May 20, 2026 - Age may be an important factor in estimating lymph node positivity in thin melanoma, according to the results of a recent study. https://www.cancernetwork.com/treatment-algorithms-with-the-oncology-brothers?page=1 Treatment Algorithms with the Oncology Brothers | CancerNetwork treatment algorithms oncology brothers cancernetwork https://www.cancernetwork.com/ CancerNetwork - Oncology News and Clinical Expertise oncology news cancernetwork clinical expertise https://www.cancernetwork.com/view/iris-6-year-data-confirm-imatinib-standard-cml-rx IRIS 6-year data confirm imatinib as standard CML Rx | CancerNetwork May 14, 2026 - Six-year results of the IRIS trial confirm imatinib (Gleevec) as the standard first-line therapy for chronic myelogenous leukemia iris year data confirm https://www.cancernetwork.com/view/perspectives-new-psa-screening-recommendations Perspectives on the New PSA Screening Recommendations | CancerNetwork May 16, 2026 - This is a very emotional issue. Any time a group claims less screening is good, I always take it with a grain of salt-yet the data certainly seem to support... on the psa screening perspectives new recommendations https://www.cancernetwork.com/view/addition-of-disease-modifying-agents-to-allogeneic-hct-shows-promise-in-mpns Addition of Disease Modifying Agents to Allogeneic HCT Shows Promise in MPNs | CancerNetwork May 16, 2026 - Investigators believe that disease modifying agents may demonstrate benefit in patients with myeloproliferative neoplasms prior to allogeneic hematopoietic... https://www.cancernetwork.com/view/chemotherapy-shortages-affecting-hematologic-cancers-due-to-production-issues Chemotherapy Shortages Affecting Hematologic Cancers Due to Production Issues | CancerNetwork May 20, 2026 - Julie M. Vose, MD, MBA, reflects on the generic drug shortages and the reasoning behind the continued pattern affecting different cancer types. hematologic cancers chemotherapy shortages due production https://www.cancernetwork.com/view/assessing-acupuncture-feasibility-in-the-oncology-treatment-paradigm Assessing Acupuncture Feasibility in the Oncology Treatment Paradigm | CancerNetwork May 15, 2026 - Ting Bao, MD, MS, suggested chemotherapy-induced neuropathy could be mitigated through acupuncture, although phase 3 clinical trial results are pending. oncology treatment assessing acupuncture feasibility paradigm https://www.cancernetwork.com/view/ai-to-accelerate-the-future-of-pancreatic-cancer-prevention-care AI to Accelerate the Future of Pancreatic Cancer Prevention/Care | CancerNetwork May 11, 2026 - Medical use of AI increases every day, and in the future, will be exponentially greater and many forms of treatment will be improved, according to Russell C.... the future pancreatic cancer ai accelerate https://www.cancernetwork.com/view/patient-profile-3-rcc-treated-with-adjuvant-pembrolizumab-postnephrectomy Patient Profile 3: RCC Treated With Adjuvant Pembrolizumab Postnephrectomy | CancerNetwork May 21, 2026 - Expert panelists review a clinical scenario of renal cell carcinoma managed with adjuvant pembrolizumab postnephrectomy based on results of the KEYNOTE-564... patient profile rcc treated adjuvant pembrolizumab https://www.cancernetwork.com/view/chemoradiation-therapy-organ-preservation-localized-male-urethral-carcinoma Chemoradiation Therapy for Organ Preservation in Localized Male Urethral Carcinoma | CancerNetwork May 19, 2026 - More research is needed to define the optimal radiotherapy and chemotherapy regimen for male urethral carcinoma. However, modern chemoradiation is a feasible... organ preservation therapy https://www.cancernetwork.com/view/managing-adverse-events-while-on-treatment-for-renal-cell-carcinoma Managing Adverse Events While on Treatment for Renal Cell Carcinoma | CancerNetwork May 19, 2026 - Laura Sanza, PhD, MPAS, PA-C, leads a discussion on communicating adverse events with patients and mitigating potential toxicities. renal cell carcinoma adverse events treatment for managing https://www.cancernetwork.com/view/are-novel-immunotherapy-combos-effective-for-indolent-lymphoma-care- Are Novel Immunotherapy Combos Effective for Indolent Lymphoma Care? | CancerNetwork May 19, 2026 - Bispecific antibodies have demonstrated adaptability and versatility when combined with immunotherapy and chemotherapy agents. lymphoma care novel immunotherapy combos effective https://www.cancernetwork.com/clinical/thyroid-cancer?page=2 Thyroid Cancer | Clinical | Page 2 | CancerNetwork thyroid cancer clinical cancernetwork https://www.cancernetwork.com/journals/oncology/oncology-vol-22-no-9 ONCOLOGY Vol 22 No 9 | Oncology | Journal | CancerNetwork oncology vol journal cancernetwork https://www.cancernetwork.com/authors/lee-ann-dietz Lee Ann Dietz | Authors | CancerNetwork lee ann dietz authors cancernetwork https://www.cancernetwork.com/view/chinese-study-finds-uproleselan-chemo-does-not-meet-os-end-point-in-r-r-aml Chinese Study Finds Uproleselan/Chemo Does Not Meet OS End Point in R/R AML | CancerNetwork May 10, 2026 - Uproleselan plus chemotherapy did not demonstrate clinical benefit over chemotherapy alone, though did show an acceptable safety profile. https://www.cancernetwork.com/clinical/leukemia?page=63 Leukemia | Clinical | Page 63 | CancerNetwork leukemia clinical cancernetwork https://www.cancernetwork.com/authors/ericson-stoen-md Ericson Stoen, MD | Authors | CancerNetwork ericson md authors cancernetwork https://www.cancernetwork.com/view/facing-forward-meeting-rehabilitation-needs-cancer-surviviors Facing Forward: Meeting the Rehabilitation Needs of Cancer Surviviors | CancerNetwork May 17, 2026 - The 5-year survival rate of cancer patients in the United States is about 66%, and today there are approximately 12 million cancer survivors in the US. facing forward meeting rehabilitation needs cancer https://www.cancernetwork.com/authors/surabhi-batra-md Surabhi Batra, MD | Authors | CancerNetwork surabhi md authors cancernetwork https://www.cancernetwork.com/view/studying-efficacy-durvalumab-and-radiation-therapy-bladder-cancer Studying the Efficacy of Durvalumab and Radiation Therapy in Bladder Cancer | CancerNetwork May 20, 2026 - We spoke with Dr. Monika Joshi on the use of radiation therapy and durvalumab in patients with locally advanced bladder cancer. https://www.cancernetwork.com/view/carcinoma-esophagus Carcinoma of the Esophagus | CancerNetwork May 17, 2026 - Carcinoma of the esophagus or the gastroesophageal junction is uncommon, accounting for approximately 1% of all malignancies in the United States [1]. An... carcinoma esophagus cancernetwork https://www.cancernetwork.com/view/use-of-inotuzumab-for-all-in-the-frontline-setting Use of Inotuzumab for ALL in the Frontline Setting | CancerNetwork May 17, 2026 - Nikesh Shah, MD, presents a trial published in Lancet Oncology in 2018 on the use of inotuzumab plus mini-CVD in the frontline setting for older patients with... for all use frontline setting cancernetwork https://www.cancernetwork.com/view/the-evolving-treatment-landscape-and-patient-perspectives The Evolving Treatment Landscape and Patient Perspectives | CancerNetwork May 14, 2026 - Drs Jain and Shah discuss the future of patient care in metastatic bladder cancer, while Mr. and Mrs. Ehas share advice for patients with bladder cancer,... patient perspectives evolving treatment landscape cancernetwork https://www.cancernetwork.com/view/non-secretory-myeloma-one-two-or-more-entities Non-Secretory Myeloma: One, Two, or More Entities? | CancerNetwork May 10, 2026 - To define the differences between the subtypes of myeloma patients, not only prospective collection of clinical and laboratory data are needed, but also... two or more non myeloma one entities https://www.cancernetwork.com/view/cell-free-dna-blood-test-may-detect-early-stage-lung-cancer Cell-Free DNA Blood Test May Detect Early-Stage Lung Cancer | CancerNetwork May 21, 2026 - Cell-free DNA, used to guide treatment of advanced lung cancer, may become a tool for early detection, based on analysis of participants in the Circulating... blood test https://www.cancernetwork.com/view/study-shows-post-mastectomy-disparities-in-breast-cancer-minority-groups Study Shows Post-Mastectomy Disparities in Breast Cancer Minority Groups | CancerNetwork May 21, 2026 - Findings speak to the need of cultural, racial, and ethnic inclusion when designing breast cancer trials and developing patient-reported outcome measures. post mastectomy breast cancer minority groups study shows https://www.cancernetwork.com/view/ruxolitinib-improves-control-dor-in-steroid-refractory-chronic-gvhd Ruxolitinib Improves Control, DOR in Steroid Refractory Chronic GVHD | CancerNetwork May 11, 2026 - Treatment with ruxolitinib improves the probability of failure-free survival compared with best available treatment among those with chronic... ruxolitinib improves control dor steroid https://www.cancernetwork.com/view/discussing-disease-progression-and-end-life-decisions Discussing Disease Progression and End-of-Life Decisions | CancerNetwork May 14, 2026 - Few of us enjoy performing a task if we feel that we are not very good at it. Furthermore, the simpler the task appears to be, the more embarrassed we feel... end of life decisions disease progression discussing cancernetwork https://www.cancernetwork.com/view/quiz-which-somatic-mutation-present-most-high-grade-ovarian-cancers Quiz: Which Somatic Mutation Is Present in Most High-Grade Ovarian Cancers? | CancerNetwork May 11, 2026 - Which somatic mutation do most high-grade serous ovarian carcinomas harbor? And what percentage of endometrioid endometrial tumors have copy-number... https://www.cancernetwork.com/view/gut-reaction-new-locale-antibody-activity Gut Reaction: New Locale for Antibody Activity | CancerNetwork May 16, 2026 - Most antibodies do their work in the bloodstream. But others may be powerless to knock out their disease-causing foes unless the confrontation takes place... gut reaction new locale antibody https://www.cancernetwork.com/view/activity-of-rivoceranib-in-adenoid-cystic-carcinoma-showcased-at-asco-2022 Activity of Rivoceranib in Adenoid Cystic Carcinoma Showcased at ASCO 2022 | CancerNetwork May 10, 2026 - Treatment with the oral VEGFR2 inhibitor rivoceranib appears to induce responses in recurrent or metastatic adenoid cystic carcinoma. adenoid cystic carcinoma https://www.cancernetwork.com/authors/filipa-lynce Filipa Lynce | Authors | CancerNetwork authors cancernetwork https://www.cancernetwork.com/view/treating-recurrent-her2-mbc-given-recent-clinical-trials Treating Recurrent HER2+ Metastatic Breast Cancer Given Recent Clinical Trials | CancerNetwork May 20, 2026 - A panel of experts reviews clinical trial data in recurrent HER2-positive metastatic breast cancer and discusses impacts on treatment selection. metastatic breast cancer clinical trials treating recurrent https://www.cancernetwork.com/view/antibody-targeted-chemotherapy-included-nccn-oncology-practice-guidelines Antibody-Targeted Chemotherapy Included in NCCN Oncology Practice Guidelines | CancerNetwork May 21, 2026 - Wyeth-Ayerst Laboratories announced recently that thousands of patients affected by acute myeloid leukemia (AML) may benefit from the new National... practice guidelines antibody targeted chemotherapy included https://www.cancernetwork.com/view/tkis-or-chemoimmunotherapy-frontline-cll-management TKIs or Chemoimmunotherapy for Frontline CLL Management? | CancerNetwork May 15, 2026 - Clinicians and patients now have several options for frontline management of chronic lymphocytic leukemia; exactly which option is preferred remains up for... for frontline cll management cancernetwork https://www.cancernetwork.com/view/critical-questions-about-rituximab-maintenance-lymphoma-patients Critical Questions About Rituximab Maintenance in Lymphoma Patients | CancerNetwork May 21, 2026 - Recent trials have demonstrated improvements in progression-free and overall survival with the inclusion of the chimeric anti-CD20 monoclonal antibody... critical questions maintenance lymphoma patients cancernetwork https://www.cancernetwork.com/authors/susana-m-campos-md-mph Susana M. Campos, MD, MPH | Authors | CancerNetwork susana campos md mph authors https://www.cancernetwork.com/authors/ronald-johnson Ronald Johnson | Authors | CancerNetwork ronald johnson authors cancernetwork https://www.cancernetwork.com/authors/rebecca-m-speck Rebecca M Speck | Authors | CancerNetwork rebecca speck authors cancernetwork https://www.cancernetwork.com/view/risk-aml-thyroid-cancer-patients-treated-radioactive-iodine Risk of AML in Thyroid Cancer Patients Treated With Radioactive Iodine | CancerNetwork May 19, 2026 - In this interview we discuss a study that examined the risk of acute myeloid leukemia in thyroid cancer patients who have been treated with surgery and... thyroid cancer https://www.cancernetwork.com/view/possible-reduce-treatment-burden-her2-positive-breast-cancer Possible to Reduce Treatment Burden in HER2-Positive Breast Cancer? | CancerNetwork May 19, 2026 - This video examines the idea of using clinical features (age, tumor size) to reduce treatment burden in patients with HER2-positive breast cancer. breast cancer possible reduce treatment burden https://www.cancernetwork.com/view/new-antiangiogenesis-agent-promising-glioblastoma New Antiangiogenesis Agent Promising in Glioblastoma | CancerNetwork May 17, 2026 - The oral multitargeted tyrosine kinase inhibitor cediranib (Recentin, AstraZeneca), known experimentally as AZD2171, alleviated edema and showed an improvement... new agent promising glioblastoma cancernetwork https://www.cancernetwork.com/authors/jen-jane-liu-md Jen-Jane Liu, MD | Authors | CancerNetwork jen jane liu md authors https://www.cancernetwork.com/authors/sundhar-ramalingam-md Sundhar Ramalingam, MD | Authors | CancerNetwork md authors cancernetwork https://www.cancernetwork.com/view/ruxolitinib-receives-positive-nice-opinion-for-polycythemia-vera Ruxolitinib Receives Positive NICE Opinion for Polycythemia Vera | CancerNetwork May 21, 2026 - Data from a previous MPN LANDMARK survey highlight that many patients with polycythemia vera experience symptoms that lead to reduced quality of life. polycythemia vera ruxolitinib receives positive nice https://www.cancernetwork.com/authors/michael-perry-md Michael Perry, MD | Authors | CancerNetwork michael perry md authors cancernetwork https://www.cancernetwork.com/view/pimicotinib-significantly-improves-responses-vs-placebo-in-tgct Pimicotinib Significantly Improves Responses Vs Placebo in TGCT | CancerNetwork May 16, 2026 - Treatment with pimicotinib also yields meaningful improvements in stiffness and pain symptoms among patients with TGCT in the phase 3 MANEUVER study. significantly improves responses vs placebo https://www.cancernetwork.com/view/journal-paolo-tarantino-md-spotlights-treatment-trends-for-breast-cancer-awareness-month Paolo Tarantino, MD, Spotlights Treatment Trends for Breast Cancer Awareness Month | CancerNetwork May 21, 2026 - In an interview for Breast Cancer Awareness Month, Paolo Tarantino, MD, discusses the importance of multidisciplinary care for patients with breast cancer, the... breast cancer awareness month https://www.cancernetwork.com/view/fda-approves-ruxolitinib-tablets-for-hematologic-malignancies FDA Approves Ruxolitinib Tablets for Hematologic Malignancies | CancerNetwork May 10, 2026 - Data showing the bioequivalence of extended-release ruxolitinib tablets vs reference ruxolitinib supported the FDA approval across multiple indications. for hematologic malignancies fda approves ruxolitinib tablets https://www.cancernetwork.com/view/dostarlimab-combo-yields-efficacy-results-in-advanced-nsclc Dostarlimab Combo Yields Efficacy Results in Advanced NSCLC | CancerNetwork May 19, 2026 - Results from the phase 2 PERLA trial showed an improved objective response and overall survival in treatment with dostarlimab plus chemotherapy in patients... advanced nsclc combo yields efficacy results https://www.cancernetwork.com/view/tovecimig-paclitaxel-meets-pfs-misses-os-end-points-in-2l-biliary-tract-cancer Tovecimig/Paclitaxel Meets PFS, Misses OS End Points in 2L Biliary Tract Cancer | CancerNetwork May 15, 2026 - Tovecimig plus paclitaxel yielded a median OS of 8.9 months vs 9.4 months with control in second-line biliary tract cancer in the phase 2/3 COMPANION-002 trial. https://www.cancernetwork.com/view/fda-clears-chromogranin-a-immunoassay-in-gastroenteropancreatic-nets FDA Clears Chromogranin A Immunoassay in Gastroenteropancreatic NETs | CancerNetwork May 14, 2026 - Clearance of an automated immunoassay allows practices to measure chromogranin A concentration in human serum, thereby tracking disease progression in those... chromogranin a fda clears immunoassay nets https://www.cancernetwork.com/view/sacituzumab-govitecan-earns-breakthrough-therapy-designation-in-es-sclc Sacituzumab Govitecan Earns Breakthrough Therapy Designation in ES-SCLC | CancerNetwork May 16, 2026 - Sacituzumab govitecan showed promising response and survival data in the extensive-stage small cell lung cancer cohort of the phase 2 TROPiCS-03 trial. sacituzumab govitecan earns breakthrough therapy designation https://www.cancernetwork.com/view/binimetinib-improves-pfs-nras-mutated-metastatic-melanoma Binimetinib Improves PFS in NRAS-Mutated Metastatic Melanoma | CancerNetwork May 19, 2026 - The MEK inhibitor binimetinib resulted in improved progression-free survival and response rates vs dacarbazine in patients with NRAS-mutated metastatic... metastatic melanoma improves pfs mutated cancernetwork https://www.cancernetwork.com/view/join-cancernetwork Join CancerNetwork | CancerNetwork join cancernetwork https://www.cancernetwork.com/view/urine-based-dna-test-can-help-diagnose-bladder-tumors Urine-Based DNA Test Can Help Diagnose Bladder Tumors | CancerNetwork May 16, 2026 - A novel urine-based DNA test was effective at detecting bladder cancer, and in particular at identifying patients with gross hematuria who do not require... dna test bladder tumors urine based help https://medwinpublishers.com/article-description.php?artId=3976 Medwin Publishers | Identification of Important Key Regulators in Cervical CancerNetwork Jun 26, 2019 - Cervical cancer is a major cause of death in women. The total number of genes that are associated with cervical cancer is 3099. We created a PPI network and... publishers identification important key regulators https://www.cancernetwork.com/authors/david-fennelly-md-mrcpi David Fennelly, MD, MRCPI | Authors | CancerNetwork david md authors cancernetwork https://www.cancernetwork.com/view/osimertinib-standard-care-t790m-positive-nsclc Osimertinib Standard of Care in T790M-Positive NSCLC | CancerNetwork May 16, 2026 - Second-line treatment with osimertinib resulted in significantly better progression-free survival compared with chemotherapy alone in patients with EGFR-T790M... standard of care positive nsclc cancernetwork https://www.cancernetwork.com/year-in-review Year In Review | CancerNetwork year in review cancernetwork